NYSE$PHR

Phreesia Inc · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

Phreesia reported fiscal Q4 2025 revenue of $109.7M with a net loss of $6.4M.

Total revenue was $109.7 million for the quarter ended January 31, 2025, up 15% year over year. Net loss narrowed to $6.4 million from $30.6 million a year ago as adjusted EBITDA reached $16.4 million.

  • Q4 revenue $109.7M (+15% YoY).
  • Net loss $(6.4)M; adjusted EBITDA $16.4M.
  • Average healthcare services clients 4,341 (+10% YoY).
  • FY26 revenue outlook $472M–$482M.

Headline financials

Total Revenue

$110M

Previous: $95M+15.4%
EPS (adj)

-$0.11

Previous: -$0.56+80.4%
Adjusted EBITDA

$16.4M

No prior period
Patient Payment Volume

$1.08B

No prior period
Capital Expenditures

-$7.06M

Previous: -$7.86M+10.2%
Net Income

-$6.39M

Previous: -$30.6M+79.1%
Operating Income

-$7.61M

Previous: -$29.6M+74.3%
Gross Profit

$69.2M

Previous: $54.8M+26.3%
R&D Expense

$29.6M

Previous: $29.9M-0.8%

Revenue & EPS history

Phreesia · Revenue · Quarterly

$110M

Q4 2025+15.4%vs Q4 2024
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Phreesia · $91.6M total across 3 segments · Q3 2024

  • Subscription Services
    $42.6M+29.1%
  • Network Solutions
    $25.8M+26.0%
  • Payment Processing
    $23.2M+18.3%

Forward guidance

Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.

Tailwinds

  • Pipeline progress and partnership economics.
  • Cash supports near-term operating plans.

Headwinds

  • Operating losses until commercial scale.
  • Financing and trial outcomes affect funding costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-1.6%

Avg return

Earnings day

+2.5%

Avg return

5 days after

+2.0%

Avg return

30 days after

54%

15 / 28 earnings

Positive

+21.4%

Q2 2023

Best reaction

-26.3%

Q4 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-26.3%-1.1%
Q1 2027+2.3%+13.3%
Q3 2026-22.8%-19.2%-16.0%
Q2 2026-9.8%-18.8%-25.4%
Q1 2026-6.6%-0.2%+14.2%
Q4 2025+6.9%+14.6%+1.1%
Q3 2025+11.1%+14.8%+30.8%
Q2 2025+7.9%+0.5%-6.8%
Q1 2025-13.3%-14.7%-2.9%
Q4 2024+1.7%-0.7%+1.0%
Q3 2024+17.8%+18.8%+45.2%
Q2 2024-21.2%-27.1%-39.1%
Q1 2024+3.6%+10.3%+4.0%
Q4 2023-13.5%-10.0%-5.7%
Q3 2023+18.7%+34.8%+20.0%
Q2 2023+21.4%+28.2%+4.9%
Q1 2023+11.9%+17.5%+40.1%
Q4 2022-11.9%+1.3%-23.6%
Q3 2022-20.2%-20.9%-32.9%
Q2 2022-12.4%-6.2%-15.4%
Q1 2022+6.6%+12.7%+24.2%
Q4 2021+2.5%+8.4%+3.3%
Q3 2021+7.3%+18.1%+16.2%
Q2 2021-3.2%-9.2%+3.5%
Q1 2021-6.7%-10.5%-13.1%
Q4 2020+4.2%+18.1%+30.6%
Q3 2020-1.0%-8.8%-6.9%
Q2 2020+0.2%+7.3%+1.2%
Q1 2020
Q4 2019
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro